Systemic Organ Communication in STEMI

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03539133

Acronym

SYSTEMI

Enrollment

1000

Registered

2018-05-29

Start date

2017-10-18

Completion date

2030-06-01

Last updated

2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-segment Elevation Myocardial Infarction (STEMI)

Keywords

STEMI, infarction, coronary artery disease, comorbidities, diabetes, anemia

Brief summary

Despite progress in pre-hospital care, ambulance logistics, pharmacotherapy and PPCI techniques, ST-segment elevation myocardial infarction (STEMI) continues to confer a substantial burden of morbidity and mortality. Within the STEMI population, there is a spectrum of higher and lower risk patients. The aim of this cohort study is to collect prospectively and systematically clinical research data from STEMI patients. This cohort study is an open-end observational study to identify master switches in myocardial ischemia.

Interventions

OTHERcollection of clinical data

prospectively and systematically collection of clinical research data from STEMI patients

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients suffering from STEMI

Exclusion criteria

* \< 18 years

Design outcomes

Primary

Measure	Time frame	Description
Left-ventricular function	6 months	* LV-EF \< 40% at 6 months * Δ LV-EF ≥ 5% between day 5 of hospitalization and 6 months
Left-ventricular remodeling	6 months	Δ LVEDV ≥ 20% or Δ LVESV ≥ 15% between day 5 of hospitalization and 6 months
Myocardial texture	on day 5 of hospitalization and 6 months	* Infarct/Scar size \> 17.9% or MVO (yes) or IMH (yes) on day 5 of hospitalization or at 6 months * remote zone ΔECV between day 5 of hospitalization and 6 months
Patency rate	6 months	Coronary patency rate

Secondary

Measure	Time frame	Description
All cause mortaltiy	12 months	All cause mortaltiy
MACCE	12 months	cardiovascular death, non-fatal stroke or myocardial infarction
Re-Hospitalisation due to heart failure	12 months	Re-Hospitalisation due to heart failure

Countries

Germany

Contacts

CONTACTChristian Jung, MD, PhD

christian.jung@med.uni-duesseldorf.de+492118118800

CONTACTFlorian Bönner, MD,

florian.boenner@med.uni-duesseldorf.de+492118118800

PRINCIPAL_INVESTIGATORChristian Jung, MD, PhD

Division of Cardiology, Pulmonary Disease and Vascular Medicine

STUDY_CHAIRMalte Kelm, MD